Effectiveness of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effectiveness of hexaminolevulinate (Hexvix) in the diagnosis and treatment of patients with non-invasive bladder cancer and if it results in a change in patient management.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GE Healthcare
• Treatments: Aminolevulinic Acid

Criteria

Inclusion Criteria:

• Patients over 18 years of age.

• Patients of either sex.

• Patients with documented or highly suspected non-invasive bladder cancer.

Exclusion Criteria:

• Patients with hypersensitivity to the drug substance or any excipient of Hexvix.

• Patients with porphyry.

• Women of childbearing age.

• Patients at a high risk of suffering extensive bladder inflammation e.g. patients after intravesical BCG treatment, patients with moderate or severe leukocyturia or patients undergoing recent bladder surgery.